Target ALS announces the second round of recipients in 2020 receiving grants to fund studies focused on discovering and developing ALS biomarkers, in a media release.
This funding round, resulting from a call for proposals issued in the spring, builds on $5 million in grants awarded to projects earlier this year, in collaboration with The Association for Frontotemporal Degeneration (AFTD) targeting applicable treatments and biomarkers for both ALS and FTD, according to the release.
“Listening to what our scientific community needs to advance their work, and responding with innovative approaches and resources is how we help exponentially advance ALS research.
“We are now at a juncture where reliable biomarkers are an increasingly acute need. We look forward to the contribution of these consortia in this search, which could greatly improve the lives of ALS patients.”
— Target ALS CEO, Manish Raisinghani, MBBS, PhD
These Four Projects Are Receiving Funding
Four projects were selected by the Target ALS Independent Review Committee based on their potential to advance ALS biomarker discovery and development.
The members of the selected consortia receiving funding are:
- Ruth Luthi-Carter (AC Immune), Ghazaleh Sadri-Vakili, Clotilde Lagier-Tourenne, Steven Arnold and James Berry (Massachusetts General Hospital)
- Yi Chen (Biogen), Jiou Wang and Phil Wong (Johns Hopkins University)
- Erez Eitan (NeuroDex Inc.), Sabrina Paganoni (Massachusetts General Hospital), Jeff Rothstein (Johns Hopkins University)
- Toby Ferguson (Biogen), Tim Miller and Cindy Ly (Washington University), Randall Bateman (Washington University)
These grants will be awarded as one of three key pillars within The Target ALS Diagnosis Initiative, a $15 million comprehensive effort to discover ALS biomarkers that Target ALS recently announced. This research initiative was developed in response to the input of over 100 scientists and other thought leaders, who universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.
The grantees will also have open access to all of the tools and resources made available through the organization in order to inform and advance their work, including human biosamples, genomic datasets, and stem cells.
The Target ALS Diagnosis Initiative will also include a 5-year natural history study, as well as a Biofluid and Genomics core that will exponentially improve the access to, and impact of, human biosamples on research. This new core is the eighth in a suite of resources offered by Target ALS to scientists worldwide with no strings attached.
Details of the 2020 ALS Biomarker Funding Awards:
1 – AC Immune’s high-sensitivity biofluid assays for detection of TDP-43 as an ALS biomarker
Ruth Luthi-Carter (AC Immune), Ghazaleh Sadri-Vakili, Clotilde Lagier-Tourenne, Steven Arnold and James Berry (Massachusetts General Hospital)
The accumulation of abnormal forms of the Transactive Response DNA-Binding Protein (TDP-43) is a prevalent feature of amyotrophic lateral sclerosis (ALS). Although pathological TDP-43 can be detected in brain tissue post-mortem, current bioassays are insufficient to quantify these species in patients, limiting their ability to accurately diagnose and track disease progression. Leveraging its proprietary SupraAntigenTM technology platform, AC Immune has generated a range of highly specific TDP-43-binding antibodies that are designed to reliably and non-invasively quantify neuropathological forms of TDP-43 in biofluids from people living with ALS. The grant will accelerate development of these novel antibody-based tests into robust assays suitable for use in ALS clinic and trials. Planned studies under this grant will evaluate the ability of AC Immune’s antibodies to identify ALS, correlate with disease evolution and predict clinical progression.
AC Immune’s expertise in molecular diagnostics and the biochemical and clinical expertise of the Healey Center for ALS at Massachusetts General Hospital will significantly facilitate the development and validation of these new assays. This collaboration will ensure progress toward establishing biomarkers helpful in diagnosis and staging of ALS.
2 – Identification of novel biomarkers for TDP-43-associated protein expression and signaling in longitudinal CSF samples
Yi Chen (Biogen), Jiou Wang and Phil Wong (Johns Hopkins University)
The altered protein homeostasis is a common pathogenic theme across major neurodegenerative disease. The discovery of TDP-43 cytoplasmic aggregates occurring in neurons and glia cells as the central pathological hallmark in ALS and FTD led to a flurry of investigations designed to clarify how TDP-43 aggregation drives neuronal loss. However, cells with cytoplasmic aggregates invariably exhibit nuclear clearance of TDP-43, suggesting the possibility that loss of TDP-43 function could underlie cell death in ALS-FTD. Subsequent studies suggest that the loss of TDP-43 functions and signaling are closely involved in disease processes.
The goal of this project is to identify biomarkers associated with TDP-43 functions and related signaling pathways. Since the TDP-43 proteinopathy is the most predominant pathological marker of ALS, identification of biomarkers on TDP-43 functions would allow better monitoring of the disease in patients to enable clinical trial testing. Our study is designed to search for novel biomarkers for TDP-43-associated protein expression and signaling in patients’ tissues and biofluids. The study will build on our research on the TDP-43 functions and signaling pathways and the industrial experience in biomarker identification.
3 – Neuron-derived exosomes as a biomarker platform for Amyotrophic lateral sclerosis
Erez Eitan (NeuroDex Inc.), Sabrina Paganoni (Massachusetts General Hospital), Jeff Rothstein (Johns Hopkins University)
Extracellular vesicles (EVs) are nanosized lipid vesicles released by cells in all tissues and contain proteins and RNA cargo that reflect their cell of origin. Isolation of Neuron-Derived Extracellular vesicles (NDEs) from the blood is an innovative liquid biopsy option in neurology, with a high potential to generate novel diagnostic, prognostic, monitoring and pharmacodynamic biomarkers in ALS.
The partners to this consortium have already demonstrated that the protein cargo in the NDEs of sporadic ALS patients is different from controls and could potently be utilized for accurate diagnosis. The goals of this consortium are to: Expand and finalize the biomarker signature measured within isolated NDEs; provide a better resolution to the correlation between the NDEs’ cargo, postmortem brain and induced pluripotent stem cells derived neurons from the same individuals; and test the biomarker signature in a larger patient population.
4 – Characterization of Neurofilament light chain isoforms and post-translational modifications in blood and CSF of ALS patients using mass spectrometry
Toby Ferguson (Biogen), Tim Miller and Cindy Ly (Washington University), Randall Bateman (Washington University)
Neurofilaments (NFs) are key cytoskeletal proteins that regulate axon integrity and have immense potential as a biomarker for neuronal injury and neurodegenerative disease. In particular, neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) have emerged as promising CSF and serum biomarkers for ALS based on the ability of ELISA-based methods to discriminate ALS from both healthy controls and disease mimics. Studies also suggest that NF concentrations may correlate with disease severity and survival.
However, existing immunoassay methods are unable to discriminate between alternative isoforms or post-translational modifications that may occur in the disease state. In contrast, high-resolution proteomic analyses can uncover disease-specific modifications such as truncations or chemical modifications that may better reflect disease characteristics. For instance, a proteomic approach used by Dr. Randall Bateman to examine tau in Alzheimer’s disease (AD) determined that phosphorylation at specific sites, such as ptau 217 or ptau 181, preferentially occurs in AD, correlates with pathology, and is an early, strong predictor of disease onset that outperforms total tau levels. This collaboration proposes to characterize the native isoforms of NF in CSF and blood of ALS and controls with mass spectrometry to identify novel disease-specific isoforms and evaluate their prognostic capability and performance as pharmacodynamic markers.
[Source(s): Target ALS Foundation, PRWeb]
Related Content:
Target ALS Launches Effort to Discover ALS Biomarkers
Target ALS and Spartan Join Forces for the Hardest Fight
